Freenome

Private

Biotech company developing AI-powered multiomics blood tests for early cancer detection. Its platform analyzes cell-free DNA, methylation patterns, and protein biomarkers from routine blood draws to screen for cancers in their earliest stages. Lead product SimpleScreen targets FDA approval for colorectal cancer screening.

Founders Gabriel Otte, Riley Ennis, Charles Roberts
CEO Gabriel Otte

Company

Founded
2014
Headquarters
South San Francisco, California, United States
Employees
201-500

Financials

Total Funding
$1.3B
Last Valuation
$2.2B
Revenue (ARR)
pre-revenue
Sectors
Artificial Intelligence Healthtech Biotech Data & Analytics
www.freenome.com Twitter Blog

Funding History

7 rounds
Series E Feb 15, 2024
$254M
Valuation: $2.2B
Roche (Lead) Andreessen Horowitz BrightEdge Ventures (American Cancer Society) ARK Invest ArrowMark Partners ARTIS Ventures Bain Capital Life Sciences Cormorant Asset Management DCVC Eventide Asset Management Intermountain Ventures Perceptive Advisors Polaris Partners Pura Vida Investments Quest Diagnostics RA Capital Management Sands Capital Section 32 Squarepoint Capital T. Rowe Price
Undisclosed Jan 11, 2022
$290M
Roche (Lead)
Series D Dec 7, 2021
$300M
Perceptive Advisors (Lead) RA Capital Management (Lead) Andreessen Horowitz Bain Capital Life Sciences Catalio Capital Management Cormorant Asset Management DCVC Farallon Capital Management Fidelity Management & Research GV Janus Henderson Kaiser Permanente Novartis Polaris Partners Ridgeback Capital Management Roche Rock Springs Capital Sands Capital Section 32 Soleus Capital T. Rowe Price ArrowMark Partners Byers Capital Eventide Asset Management HBM Healthcare Investments Intermountain Ventures Logos Capital Pura Vida Investments Suvretta Capital Management ARTIS Ventures BrightEdge Ventures (American Cancer Society)
Series C Aug 26, 2020
$270M
Bain Capital Life Sciences (Lead) Perceptive Advisors (Lead) Fidelity Management & Research Janus Henderson Farallon Capital Management Rock Springs Capital Cormorant Asset Management EcoR1 Capital Catalio Capital Management RA Capital Management T. Rowe Price Sands Capital Andreessen Horowitz DCVC GV Novartis Polaris Partners Roche Soleus Capital Section 32
Series B Jul 24, 2019
$160M
RA Capital Management (Lead) Polaris Partners (Lead) Perceptive Advisors T. Rowe Price Roche Kaiser Permanente BrightEdge Ventures (American Cancer Society) Andreessen Horowitz GV DCVC Section 32 Verily Life Sciences
Series A Mar 1, 2017
$65M
Andreessen Horowitz (Lead) GV Polaris Partners Innovation Endeavors S28 Capital Asset Management Ventures CRV AME Cloud Ventures Allen & Company Founders Fund DCVC
Seed Jun 9, 2016
$6M
Andreessen Horowitz (Lead) Founders Fund DCVC Third Kind Venture Capital

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.